

James F. Kenney, Mayor Thomas Farley, MD, MPH, Health Commissioner Caroline Johnson, MD, Deputy Commissioner Coleman Terrell, AACO Director



AIDS Activities Coordinating Office (AACO) Surveillance Report 2015 HIV/AIDS in Philadelphia

Cases Reported through June 2016

Chrysanthus Nnumolu, MD, MPH, HIV Surveillance Program Manager Kathleen A. Brady, MD, Medical Director/Medical Epidemiologist Melissa Miller, MPH, Epidemiologist Tanner Nassau, MPH, Epidemiologist

Published: September 2016

Suggested Citation

Philadelphia Department of Public Health, AIDS Activities Coordinating Office Surveillance Report, 2015. Philadelphia, PA: City of Philadelphia; September 2016.

Cover photography by Philadelphia Convention & Visitors Bureau

Contributors and editors for this issue:

HIV Surveillance Staff Barbara Allen Caroline Eves Shirley Goss Juanita Johnson Althea Kirkland Violet Lippincott Erika Solomon Niya Spells Jessika Thompson Ruth Trino <u>Data Management Staff</u> Emily Anderson

Makeda Carroll Antonios Mashas Melissa Miller Tanner Nassau

Security and Confidentiality

All information about HIV/AIDS patients is strictly confidential and is collected for legitimate public health purposes. Confidentiality of HIV/AIDS case reports is of critical importance to maintaining effective HIV/AIDS surveillance. Federal, state, and local health departments have implemented procedures and policies to assure the confidentiality and security of HIV/AIDS data. CDC is prohibited from accepting patient names, and before records are transmitted electronically, all information is encrypted by a computer program. In addition, strict guidelines govern the release of reports similar to this one, which ensure that HIV/AIDS data are not presented in such a way as to possibly identify any individual with HIV/AIDS. Maintenance of confidentiality and security safeguards are critical for federal funding and are a top priority within the Philadelphia HIV/AIDS Surveillance Unit.

This publication was supported by the Grant or Cooperative Agreement Number, **U62PS003959-04**, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.

Contents

| Executive Summary | 4 |
|---|----|
| Figure 1. HIV Care Continuum, Philadelphia, 2015 | 6 |
| Figure 2. The HIV Care Continuum in the United States, 2013 | 6 |
| Table 1. Newly Diagnosed HIV Disease | 7 |
| Table 2. Newly Diagnosed HIV Disease by Race | 8 |
| Figure 3: Rates of Newly Diagnosed HIV Disease by Race | 8 |
| Table 3. Newly Diagnosed HIV Disease by Sex at Birth | 9 |
| Table 4. AIDS Diagnoses by Year | 10 |
| Figure 4. Philadelphia HIV Diagnoses, AIDS Diagnoses, Deaths, and People Living with HIV/AIDS by Year | 11 |
| Figure 5. Rates of Newly Diagnosed HIV/AIDS by Transmission Category | 11 |
| Table 5. Persons Living with HIV (Non-AIDS) and AIDS Cases | 12 |
| Table 6. Persons Living with HIV/AIDS by Race | 13 |
| Table 7. Persons Living with HIV/AIDS by Sex at Birth | 14 |
| Table 8. Persons Living with HIV/AIDS by Gender Identity | 15 |
| Map 1. Persons Living with HIV/AIDS by Census Tract | 16 |
| Map 2. Newly Diagnosed HIV by Census Tract | 17 |
| Table 9. Prevalence Rates of HIV/AIDS in Philadelphia | |
| Figure 6. Prevalence Rates of HIV/AIDS by Race and Transmission Category | 19 |
| Table 11. Cumulative Adult HIV (Non-AIDS) and AIDS Cases | 20 |
| Table 12. Concurrent HIV/AIDS | 21 |
| Table 13. Incidence Estimates | 22 |
| Table 14. Perinatal Exposures by Selected Demographics (a) and Clinical Characteristics (b) | 23 |
| Table 15. Persons Living with HIV and Hepatitis B or C Co-infection | 24 |
| Definitions | 25 |
| Reporting Information | 26 |

Executive Summary

The AIDS Activities Coordinating Office Surveillance Report is the annual report presenting data on HIV/AIDS cases in the city of Philadelphia. Data in this report includes persons diagnosed through December 31, 2015 and reported through June 30, 2016.

The number of newly diagnosed HIV cases has been on a steady decline since the mid-2000s (Figure 4). In addition to these declines, Philadelphia has a similar percentage of HIV-positive individuals in care when compared to national rates. This report highlights these and other notable trends observed through 2015. By collecting, analyzing, and publishing the most recent data available, AACO is helping our partners initiate, target, and focus their outreach, testing, prevention, and care approaches across the city to ensure that resources and efforts are directed to populations in greatest need.

New Tables

The authors would like to point out that the 2015 HIV Surveillance Report includes new information on perinatal exposures (Table 14) as well as co-infections of Hepatitis B and C with HIV (Table1 & Table 15).

HIV CONTINUUM OF CARE

The HIV Continuum of Care is a data driven tool focusing on the diagnosis and care of individuals living with HIV. Engaging HIV patients in care is critical to both individual health as well as slowing the spread of the disease. The Continuum highlights the percentage of people living with HIV at various levels of engagement in care. The report highlights various areas in which Philadelphia is exceeding national outcomes. The Continuum (Figure 1) includes the percentage of people with new diagnoses who were linked to care; the percentage of people who were retained in care; and the percentage of people who were virally suppressed based on all persons living with HIV (both diagnosed and undiagnosed). Nine out of ten (91%) people diagnosed with HIV in 2015 were linked to HIV medical care within 3 months of their diagnosis. However, just under half (49%) of all people living with HIV in Philadelphia were retained in HIV medical care in 2015, defined as two or more medical visits at least 90 days apart. In addition, 52% of all people living with HIV in Philadelphia were virally suppressed at their most recent viral load in 2015 (regardless of if their retention in care status). Identifying new opportunities to improve linkage to care, retention in care, and viral suppression are vital to improving the health of HIV-

positive individuals and reducing the rate of HIV transmission.

WHO IS MOST AFFECTED?

Individuals aged 13-24 accounted for 25.1% of all newly diagnosed HIV infections in 2015 (Table 1). Those whose sex at birth was male (78%), and those reported as MSM (57%) made up the largest proportions of new diagnoses. New AIDS diagnoses in Philadelphia were comprised primarily of males (71%), with heterosexuals (41%), and those aged 50 and older (30%) representing the largest transmission and age categories, respectively (Table 4). The rate of new HIV diagnoses is higher among MSM (1,122 per 100,000) compared to PWID (137 per 100,000) and high risk heterosexuals (72 per 100,000) (Figure 5). Additionally, the rate of new diagnoses appears to be increasing among MSM and decreasing among PWID and heterosexuals (Figure 5). Among people living with HIV/AIDS infected through 2015, the highest morbidity is among those who were born male (72%), MSM (35%), and those aged 50 and older (49%). Non-Hispanic Blacks continue to be affected by HIV more than any other race/ethnicity group; they represent 72% of all newly diagnosed cases, 75% of newly diagnosed AIDS, and 64% of all prevalent cases. Of all cases newly diagnosed in 2015, 20% were concurrent HIV/AIDS diagnoses (Table 12). Concurrent HIV/AIDS diagnoses represent a missed opportunity for early HIV diagnosis. While the overall number of concurrent diagnoses has gone down since 2011, certain subpopulations have had better outcomes than others. Between 2011 and 2015, concurrent diagnoses among MSM (23% vs 17%) and PWID (26% vs 10%) have fallen below the citywide average of 19.5%, but the same is not true for Heterosexuals (32% vs 25%).

RACIAL/ETHNIC DISPARITIES

Racial/ethnic health disparities in Philadelphia persist and mirror disparities observed across the nation. In 2015, the rates of new HIV diagnoses in Philadelphia were highest among Non-Hispanic Blacks (61.7 per 100,000) followed by Hispanics (41.1 per 100,000) and Non-Hispanic Whites (10.0 per 100,000) (Figure 3). The overall number of reported HIV cases among Non-Hispanic Blacks is almost twice that of Non-Hispanic Whites and Hispanics combined.

Disparities are also evident in HIV Incidence Estimates. In 2014, an estimated 57% of new infections for individuals 13 and older occurred among non-Hispanic blacks (Table 13). Identifying and eliminating these disparities is critical to slowing the spread of the HIV epidemic.

ESTIMATES OF HIV INCIDENCE

HIV incidence refers to the number of new infections in a given time period. The majority of new infections occurred among men, persons aged 13-24, and MSM (Table 13). An estimated 43.8% of new infections occurred among youth age 13-24 in 2014. The significant declines in recent HIV infections are due, in part, to decreases in new infections among heterosexuals and people who inject drugs. These estimates provide valuable information on where additional education and prevention efforts are needed. **MIGRATION**

Historically, HIV/AIDS surveillance has been based on geographical location at the time of HIV or AIDS diagnoses. Migrations were assumed to either be negligible or in migration and out migration were assumed to be roughly equal. HIV/AIDS surveillance increasingly focuses on the individuals currently living in a jurisdiction, rather than those diagnosed in the jurisdiction. While Philadelphia has seen between 500 and 700 new cases a year for the past several years, the total population of people living with HIV/AIDS in Philadelphia has remained stable due to a proportionate number of individuals moving out of Philadelphia or dying. Thus current residents, rather than those diagnosed locally, are the focus of our incare and viral suppression measures in the HIV Care Continuum.

EMERGING ISSUES

Lifetime Risk Estimates

In February 2016, the Centers for Disease Control and Prevention released lifetime risk estimates for HIV infection by sex at birth, age, race, and exposure groups. Overall, they estimated that the lifetime risk for HIV diagnosis for MSM was 1 in 6 (1:6), significantly higher than men who inject drugs (1:36), women who inject drugs (1:23), heterosexual men (1:473), and heterosexual women (1:241). Furthermore, they estimated the lifetime risk for African American MSM at 1:2, Hispanic/Latino MSM at 1:4 and White MSM at 1:11. These numbers reflect national data collected on individuals diagnosed with HIV between 2009 and 2013, as well as census data and published population proportions for risk groups. While the methods used to calculate these estimates are sound, there are several limitations. By the end of 2016, Philadelphia plans to

release more detailed estimates of lifetime risk for HIV infection among the local population. Although the national estimates and future local estimates may not be exact, they highlight important difference in lifetime risk for HIV infection among subpopulations. Lifetime risk estimates should be used to guide HIV prevention programming and evaluation. For more information on the national lifetime risk estimates for HIV infection, visit

http://www.cdc.gov/nchhstp/newsroom/2016/croipress-release-risk.html.


PrEP

Pre-Exposure Prophylaxis, or PrEP, is a daily medication taken by individuals at high risk for HIV infection to lower their chances of getting infected. In the summer of 2014, 544 MSM were interviewed as part of the National HIV Behavioral Surveillance (NHBS) project and 269 (49.4%) reported some knowledge of PrEP. NHBS surveys conducted in previous years among high risk heterosexuals and people who inject drugs demonstrated a smaller proportion of each respective risk group had any knowledge of PrEP. While PrEP can reduce an individual's chances of acquiring HIV, it is not effective when not taken as directed. Adherence to PrEP must be stressed by providers and condom usage must still be encouraged.

Transgender Persons

The quality of data on transgender individuals has not improved at the same pace as surveillance data on the overall population. Some of these differences are attributed to the lack of a gender identity variable in the surveillance system and most medical records before 2009, making it difficult to determine gender identity for individuals diagnosed prior to the addition of these variables to the current data system. Furthermore, many transgender persons are misclassified as men who have sex with men. In attempt to reexamine issues surrounding the quality of transgender data, Table 8 presents demographic information based on gender identity and reclassifies transmission risk reported as MSM and heterosexual contact into one category called sexual contact. Further understanding of the risk behaviors and needs of transgender persons is needed to inform best practices for treatment and prevention in this population. Efforts to improve data on transgender individuals are ongoing.





Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office




Figure 2. The HIV Care Continuum in the United States, 2013

Source: Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives using HIV surveillance data—United States and 6 dependent areas, 2014. *HIV Surveillance Supplemental Report 2016;* 21(No. 4). http://www.cdc.gov/hiv/library/reports/surveillance/. Published July 2016. Accessed August 2016

Linked to care: People diagnosed with HIV in a given calendar year who had one or more documented viral load or CD4 test within three months of diagnosis

<u>Retained in HIV Care</u>: At least one CD4 or viral load test in each 6 month period of the calendar year, with at least 90 days between the two tests <u>Suppressed Viral Load (VL)</u>: The last reported viral load of a calendar year being <200 copies/mL

Table 1. Newly Diagnosed HIV Disease (regardless of AIDS status) by Year and SelectedCharacteristics, Philadelphia Residents, 2011-2015

| | | | | Y | ear o | f Diagnos | is | | | |
|-------------------|-----|---------|-----|---------|-------|-----------|-----|---------|-----|---------|
| | | 2011 | | 2012 | | 2013 | | 2014 | | 2015 |
| | N | Col % | N | Col % | N | Col % | N | Col % | N | Col % |
| Total | 694 | 100.0 % | 737 | 100.0 % | 634 | 100.0 % | 569 | 100.0 % | 538 | 100.0 % |
| Race | | | | | | | | | | |
| Black | 486 | 70.0 % | 508 | 68.9 % | 474 | 74.7 % | 386 | 67.8 % | 390 | 72.4 % |
| Hispanic | 91 | 13.1 % | 114 | 15.4 % | 69 | 10.8 % | 71 | 12.4 % | 76 | 14.1 % |
| White | 105 | 15.1 % | 93 | 12.6 % | 68 | 10.7 % | 87 | 15.2 % | 56 | 10.4 % |
| Asian | 7 | 1.0 % | 11 | 1.4 % | 12 | 1.8 % | 13 | 2.2 % | 11 | 2.0 % |
| Multi-race | * | * | 7 | 0.9 % | 6 | 0.9 % | 8 | 1.4 % | * | * |
| Other/Unk | 0 | 0 | * | * | * | * | * | * | * | * |
| Sex at Birth | | | | | | | | | | |
| Female | 163 | 23.4 % | 196 | 26.5 % | 125 | 19.7 % | 120 | 21.0 % | 118 | 21.9 % |
| Male | 531 | 76.5 % | 540 | 73.2 % | 509 | 80.2 % | 449 | 78.9 % | 420 | 78.0 % |
| Age Category | | | | | | | | | | |
| 0-12 | * | * | * | * | * | * | * | * | * | * |
| 13-19 | 41 | 5.9 % | 33 | 4.4 % | 44 | 6.9 % | 33 | 5.7 % | 34 | 6.3 % |
| 20-24 | 125 | 18.0 % | 154 | 20.8 % | 132 | 20.8 % | 110 | 19.3 % | 101 | 18.7 % |
| 25-29 | 97 | 13.9 % | 115 | 15.6 % | 100 | 15.7 % | 87 | 15.2 % | 92 | 17.1 % |
| 30-39 | 151 | 21.7 % | 147 | 19.9 % | 129 | 20.3 % | 120 | 21.0 % | 129 | 23.9 % |
| 40-49 | 164 | 23.6 % | 154 | 20.8 % | 111 | 17.5 % | 97 | 17.0 % | 88 | 16.3 % |
| 50+ | 114 | 16.4 % | 133 | 18.0 % | 113 | 17.8 % | 121 | 21.2 % | 92 | 17.1 % |
| Transmission Risk | | | | | | | | | | |
| MSM | 286 | 41.2 % | 300 | 40.7 % | 322 | 50.7 % | 291 | 51.1 % | 304 | 56.5 % |
| PWID | 70 | 10.0 % | 83 | 11.2 % | 40 | 6.3 % | 40 | 7.0 % | 30 | 5.5 % |
| Heterosexual | 313 | 45.1 % | 313 | 42.4 % | 250 | 39.4 % | 225 | 39.5 % | 189 | 35.1 % |
| MSM/PWID | 13 | 1.8 % | 10 | 1.3 % | 8 | 1.2 % | 6 | 1.0 % | * | * |
| Pediatric | * | * | * | * | 6 | 0.9 % | * | * | * | * |
| No Risk Reported | 9 | 1.2 % | 30 | 4.0 % | 8 | 1.2 % | 6 | 1.0 % | 11 | 2.0 % |
| Co-Infections | | | | | | | | | | |
| Hepatitis B | 24 | 3.5% | 21 | 2.8% | 23 | 3.6% | 20 | 3.5% | 14 | 2.6% |
| Hepatitis C | 108 | 15.6% | 110 | 14.9% | 70 | 11.0% | 56 | 9.8% | 71 | 13.2% |
| | | | | | | | | | | · |


*Cells size < 6 are suppressed

Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office; Philadelphia Department of Public Health, Division of Disease Control, Viral Hepatitis Program

Table 2. Newly Diagnosed HIV Disease by Race and Selected Characteristics, PhiladelphiaResidents, 2015

| | | | F | Race | | |
|-------------------|-----|---------|-----|---------|----|---------|
| | E | Black | His | spanic | | White |
| | N | Col % | Ν | Col % | Ν | Col % |
| Total | 390 | 100.0 % | 76 | 100.0 % | 56 | 100.0 % |
| Sex at Birth | | | | | | |
| Female | 88 | 22.5 % | 16 | 21.0 % | 11 | 19.6 % |
| Male | 302 | 77.4 % | 60 | 78.9 % | 45 | 80.3 % |
| Age Category | | | | | | |
| 0-12 | * | * | 0 | 0 | 0 | 0 |
| 13-19 | 32 | 8.2 % | * | * | 0 | 0 |
| 20-24 | 80 | 20.5 % | 15 | 19.7 % | * | * |
| 25-29 | 71 | 18.2 % | 9 | 11.8 % | 12 | 21.4 % |
| 30-39 | 84 | 21.5 % | 23 | 30.2 % | 17 | 30.3 % |
| 40-49 | 56 | 14.3 % | 13 | 17.1 % | 12 | 21.4 % |
| 50+ | 66 | 16.9 % | 14 | 18.4 % | 10 | 17.8 % |
| Transmission Risk | | | | | | |
| MSM | 224 | 57.4 % | 36 | 47.3 % | 37 | 66.0 % |
| PWID | 10 | 2.5 % | 11 | 14.4 % | 8 | 14.2 % |
| Heterosexual | 145 | 37.1 % | 28 | 36.8 % | 9 | 16.0 % |
| MSM/PWID | * | * | 0 | 0 | * | * |
| Pediatric | * | * | 0 | 0 | 0 | 0 |
| No Risk Reported | 9 | 2.3 % | * | * | * | * |

Figure 3: Rates of Newly Diagnosed HIV Disease by Race, Philadelphia Residents, 2015



Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office

8

Table 3. Newly Diagnosed HIV Disease by Sex at Birth and Selected Characteristics,Philadelphia Residents, 2015

| | | | Sex a | t Birth | | |
|-------------------|-----|---------|-------------------|---------|---------|-------------------|
| | | Female | | | Male | |
| | N | Col % | Rate [†] | N | Col % | Rate [†] |
| Total | 118 | 100.0 % | 14.6 | 420 | 100.0 % | 58.3 |
| Race | | | | | | |
| Black | 88 | 74.5 % | 24.9 | 302 | 71.9 % | 103.8 |
| Hispanic | 16 | 13.5 % | 16.9 | 60 | 14.2 % | 64.4 |
| White | 11 | 9.3 % | 3.8 | 45 | 10.7 % | 16.5 |
| Asian | * | * | * | 9 | 2.1 % | 19.4 |
| Other/Unk | 0 | 0 | 0 | * | * | * |
| Multi-race | * | * | * | * | * | * |
| Age Category | | | | | | |
| 0-12 | * | * | * | 0 | 0 | 0 |
| 13-19 | * | * | * | 32 | 7.6 % | 41.6 |
| 20-24 | 11 | 9.3 % | 14.6 | 90 | 21.4 % | 126.4 |
| 25-29 | 15 | 12.7 % | 21.1 | 77 | 18.3 % | 119.2 |
| 30-39 | 45 | 38.1 % | 42.5 | 84 | 20.0 % | 85.3 |
| 40-49 | 17 | 14.4 % | 16.9 | 71 | 16.9 % | 77.1 |
| 50+ | 26 | 22.0 % | 10.2 | 66 | 15.7 % | 34.5 |
| Transmission Risk | | | | | | |
| MSM | - | - | - | 304 | 72.3 % | 906.1 |
| PWID | 10 | 8.4 % | N/A | 20 | 4.7 % | N/A |
| Heterosexual | 97 | 82.2 % | 60.4 | 92 | 21.9 % | 81.5 |
| MSM/PWID | - | - | - | * | * | * |
| Pediatric | * | * | N/A | 0 | 0 | N/A |
| No Risk Reported | 9 | 7.6 % | N/A | * | * | N/A |

*Cells size < 6 are suppressed

[†]Rates for age and race/ethnicity by sex at birth were calculated using the 2010 decennial census. MSM rates were calculated using estimates of MSM activity among males 13 and older in the last 5 years. Heterosexual rates were calculated using the number of individuals 18 and older living below the federal poverty level from the 2010 American Community Survey 1-Year Estimates. Reliable population estimates for Philadelphia PWID by sex at birth are not available.


Table 4. AIDS Diagnoses by Year and Selected Characteristics, Philadelphia Residents, 2011-2015

| | | | | Y | 'ear o | f Diagnos | is | | | |
|-------------------|-----|---------|-----|---------|--------|-----------|-----|---------|-----|---------|
| | | 2011 | | 2012 | | 2013 | | 2014 | | 2015 |
| | N | Col % | N | Col % | N | Col % | N | Col % | N | Col % |
| Total | 412 | 100.0 % | 427 | 100.0 % | 350 | 100.0 % | 265 | 100.0 % | 238 | 100.0 % |
| Race | | | | | | | | | | |
| Black | 287 | 69.6 % | 299 | 70.0 % | 247 | 70.5 % | 192 | 72.4 % | 178 | 74.7 % |
| Hispanic | 56 | 13.5 % | 63 | 14.7 % | 47 | 13.4 % | 27 | 10.1 % | 30 | 12.6 % |
| White | 58 | 14.0 % | 52 | 12.1 % | 38 | 10.8 % | 34 | 12.8 % | 22 | 9.2 % |
| Multi-race | 8 | 1.9 % | * | * | 9 | 2.5 % | 9 | 3.3 % | * | * |
| Asian | * | * | 7 | 1.6 % | 8 | 2.2 % | * | * | * | * |
| Other/Unk | 0 | 0 | * | * | * | * | * | * | * | * |
| Sex at Birth | | | | | | | | | | |
| Female | 119 | 28.8 % | 129 | 30.2 % | 99 | 28.2 % | 83 | 31.3 % | 70 | 29.4 % |
| Male | 293 | 71.1 % | 298 | 69.7 % | 251 | 71.7 % | 182 | 68.6 % | 168 | 70.5 % |
| Age Category | | | | | | | | | | |
| 13-19 | 11 | 2.6 % | 9 | 2.1 % | * | * | * | * | 6 | 2.5 % |
| 20-24 | 39 | 9.4 % | 48 | 11.2 % | 38 | 10.8 % | 15 | 5.6 % | 12 | 5.0 % |
| 25-29 | 45 | 10.9 % | 46 | 10.7 % | 44 | 12.5 % | 28 | 10.5 % | 36 | 15.1 % |
| 30-39 | 116 | 28.1 % | 93 | 21.7 % | 81 | 23.1 % | 64 | 24.1 % | 56 | 23.5 % |
| 40-49 | 112 | 27.1 % | 117 | 27.4 % | 83 | 23.7 % | 75 | 28.3 % | 57 | 23.9 % |
| 50+ | 89 | 21.6 % | 114 | 26.6 % | 101 | 28.8 % | 80 | 30.1 % | 71 | 29.8 % |
| Transmission Risk | | | | | | | | | | |
| MSM | 128 | 31.0 % | 145 | 33.9 % | 116 | 33.1 % | 86 | 32.4 % | 93 | 39.0 % |
| PWID | 58 | 14.0 % | 73 | 17.0 % | 46 | 13.1 % | 40 | 15.0 % | 35 | 14.7 % |
| Heterosexual | 208 | 50.4 % | 183 | 42.8 % | 169 | 48.2 % | 131 | 49.4 % | 98 | 41.1 % |
| MSM/PWID | 8 | 1.9 % | 9 | 2.1 % | * | * | * | * | * | * |
| Pediatric | * | * | * | * | 0 | 0 | * | * | * | * |
| No Risk Reported | 8 | 1.9 % | 16 | 3.7 % | 15 | 4.2 % | 6 | 2.2 % | 6 | 2.5 % |

*Cells size < 6 are suppressed


Note: A proportion of AIDS diagnoses in each year were diagnosed with HIV in a previous year and later progressed to AIDS

Figure 4. Philadelphia HIV Diagnoses, AIDS Diagnoses, Deaths, and People Living with HIV/AIDS by Year



^{*}Reporting of all HIV related laboratories began in 2005, allowing for surveillance of HIV non-AIDS cases

Figure 5. Rates of Newly Diagnosed HIV/AIDS per 100,000 People by Year of Diagnosis and Risk Group, 2011-2015



MSM population size based on estimates of MSM activity among males 13 and older in the last 5 years. PWID population size based on estimate of 173 active injection drug users per 10,000 population. High risk heterosexual population includes all individuals 18 and older living below poverty level. Table 5. Persons Living with HIV (Non-AIDS) and AIDS Cases by Selected Characteristics,Philadelphia Residents, 2015[†]

| | HIV (N | on-AIDS) | A | IDS | HIV | AIDS |
|-------------------|--------|----------|--------|---------|--------|---------|
| | N | Col% | N | Col% | N | Col% |
| Total | 8,234 | 100.0 % | 11,046 | 100.0 % | 19,280 | 100.0 % |
| Race | | | | | | |
| Black | 5,162 | 62.6 % | 7,097 | 64.2 % | 12,259 | 63.5 % |
| White | 1,478 | 17.9 % | 1,952 | 17.6 % | 3,430 | 17.7 % |
| Hispanic | 1,299 | 15.7 % | 1,612 | 14.5 % | 2,911 | 15.0 % |
| Multi-race | 179 | 2.1 % | 267 | 2.4 % | 446 | 2.3 % |
| Asian | 87 | 1.0 % | 98 | 0.8 % | 185 | 0.9 % |
| Other/Unk | 29 | 0.3 % | 20 | 0.1 % | 49 | 0.2 % |
| Sex at Birth | | | | | | |
| Female | 2,405 | 29.2 % | 3,063 | 27.7 % | 5,468 | 28.3 % |
| Male | 5,829 | 70.7 % | 7,983 | 72.2 % | 13,812 | 71.6 % |
| Age Category | | | | | | |
| Unknown | 47 | 0.5 % | 92 | 0.8 % | 139 | 0.7 % |
| 0-12 | 31 | 0.3 % | 6 | 0.0 % | 37 | 0.1 % |
| 13-19 | 80 | 0.9 % | 21 | 0.1 % | 101 | 0.5 % |
| 20-24 | 383 | 4.6 % | 126 | 1.1 % | 509 | 2.6 % |
| 25-29 | 933 | 11.3 % | 421 | 3.8 % | 1,354 | 7.0 % |
| 30-39 | 1,867 | 22.6 % | 1,243 | 11.2 % | 3,110 | 16.1 % |
| 40-49 | 1,936 | 23.5 % | 2,696 | 24.4 % | 4,632 | 24.0 % |
| 50+ | 2,957 | 35.9 % | 6,441 | 58.3 % | 9,398 | 48.7 % |
| Transmission Risk | | | | | | |
| MSM | 3,165 | 38.4 % | 3,586 | 32.4 % | 6,751 | 35.0 % |
| PWID | 1,467 | 17.8 % | 3,037 | 27.4 % | 4,504 | 23.3 % |
| Heterosexual | 3,073 | 37.3 % | 3,621 | 32.7 % | 6,694 | 34.7 % |
| MSM/PWID | 170 | 2.0 % | 435 | 3.9 % | 605 | 3.1 % |
| Pediatric | 128 | 1.5 % | 145 | 1.3 % | 273 | 1.4 % |
| Other | * | * | 11 | 0.0 % | 15 | 0.0 % |
| No Risk Reported | 227 | 2.7 % | 211 | 1.9 % | 438 | 2.2 % |

*Cells size < 6 are suppressed

⁺Age as of December 31, 2015

Table 6. Persons Living with HIV/AIDS by Race and Selected Characteristics, Philadelphia Residents, 2015[†]

| | | | R | ace | | |
|-------------------|--------|---------|-------|---------|-------|---------|
| | BI | ack | N | /hite | His | panic |
| | N | Col % | N | Col % | N | Col % |
| Total | 12,259 | 100.0 % | 3,430 | 100.0 % | 2,911 | 100.0 % |
| Sex at Birth | | | | | | |
| Female | 3,958 | 32.2 % | 539 | 15.7 % | 793 | 27.2 % |
| Male | 8,301 | 67.7 % | 2,891 | 84.2 % | 2,118 | 72.7 % |
| Age Category | | | | | | |
| Unknown | 93 | 0.7 % | 13 | 0.3 % | 26 | 0.8 % |
| 0-12 | 28 | 0.2 % | * | * | 6 | 0.2 % |
| 13-19 | 79 | 0.6 % | 6 | 0.1 % | 14 | 0.4 % |
| 20-24 | 397 | 3.2 % | 25 | 0.7 % | 75 | 2.5 % |
| 25-29 | 1,008 | 8.2 % | 138 | 4.0 % | 161 | 5.5 % |
| 30-39 | 1,985 | 16.1 % | 457 | 13.3 % | 519 | 17.8 % |
| 40-49 | 2,877 | 23.4 % | 774 | 22.5 % | 784 | 26.9 % |
| 50+ | 5,792 | 47.2 % | 2,016 | 58.7 % | 1,326 | 45.5 % |
| Transmission Risk | | | | | | |
| MSM | 3,789 | 30.9 % | 1,980 | 57.7 % | 725 | 24.9 % |
| PWID | 2,683 | 21.8 % | 673 | 19.6 % | 1,006 | 34.5 % |
| Heterosexual | 4,943 | 40.3 % | 548 | 15.9 % | 961 | 33.0 % |
| MSM/PWID | 346 | 2.8 % | 152 | 4.4 % | 84 | 2.8 % |
| Pediatric | 199 | 1.6 % | 20 | 0.5 % | 49 | 1.6 % |
| Other | 7 | 0.0 % | 6 | 0.1 % | * | * |
| No Risk Reported | 292 | 2.3 % | 51 | 1.4 % | 85 | 2.9 % |

*Cells size < 6 are suppressed

[†]Age as of December 31, 2015

Table 7. Persons Living with HIV/AIDS by Sex at Birth and Selected Characteristics, Philadelphia Residents, 2015[†]

| | | Sex a | at Birth | |
|-------------------|-------|---------|----------|---------|
| | Fe | male | м | ale |
| | N | Col % | N | Col % |
| Total | 5,468 | 100.0 % | 13,812 | 100.0 % |
| Race | | | | |
| Black | 3,958 | 72.3 % | 8,301 | 60.0 % |
| White | 539 | 9.8 % | 2,891 | 20.9 % |
| Hispanic | 793 | 14.5 % | 2,118 | 15.3 % |
| Multi-race | 125 | 2.2 % | 321 | 2.3 % |
| Asian | 40 | 0.7 % | 145 | 1.0 % |
| Other/Unk | 13 | 0.2 % | 36 | 0.2 % |
| Age Category | | | | |
| Unknown | 41 | 0.7 % | 98 | 0.7 % |
| 0-12 | 20 | 0.3 % | 17 | 0.1 % |
| 13-19 | 31 | 0.5 % | 70 | 0.5 % |
| 20-24 | 109 | 1.9 % | 400 | 2.8 % |
| 25-29 | 262 | 4.7 % | 1,092 | 7.9 % |
| 30-39 | 853 | 15.5 % | 2,257 | 16.3 % |
| 40-49 | 1,612 | 29.4 % | 3,020 | 21.8 % |
| 50+ | 2,540 | 46.4 % | 6,858 | 49.6 % |
| Transmission Risk | | | | |
| MSM | 0 | 0 | 6,751 | 48.8 % |
| PWID | 1,470 | 26.8 % | 3,034 | 21.9 % |
| Heterosexual | 3,695 | 67.5 % | 2,999 | 21.7 % |
| MSM/PWID | 0 | 0 | 605 | 4.3 % |
| Pediatric | 127 | 2.3 % | 146 | 1.0 % |
| Other | * | * | 12 | 0.0 % |
| No Risk Reported | 173 | 3.1 % | 265 | 1.9 % |

Enjoy safer sex for free!

Like getting busy with other guys? Get **CONDOMS**, **LUBE**, and **TEST KITS** mailed to you for free! **DoYouPhilly.org**





*Cells size < 6 are suppressed

[†]Age as of December 31, 2015

Table 8. Persons Living with HIV/AIDS by Gender Identity and Selected Characteristics, Philadelphia Residents, 2015


| | | | | | Gende | r Identity | | | | |
|---------------------------|--------|---------|-------|---------|---------|------------|-------|-----------|----------|-------------|
| | м | ale | Fer | nale | Male to | o Female | Femal | e to Male | Addition | al Identity |
| | N | Col % | N | Col % | Ν | Col % | Ν | Col % | N | Col % |
| Total | 13,615 | 100.0 % | 5,452 | 100.0 % | 198 | 100.0 % | 8 | 100.0 % | 7 | 100.0 % |
| Race | | | | | | | | | | |
| Black | 8,152 | 59.8 % | 3,946 | 72.3 % | 148 | 74.7 % | 6 | 75.0 % | 7 | 100.0 % |
| White | 2,878 | 21.1 % | 538 | 9.8 % | 13 | 6.5 % | * | * | 0 | 0 |
| Hispanic | 2,091 | 15.3 % | 790 | 14.4 % | 29 | 14.6 % | * | * | 0 | 0 |
| Multi-race | 317 | 2.3 % | 125 | 2.2 % | * | * | 0 | 0 | 0 | 0 |
| Asian | 142 | 1.0 % | 40 | 0.7 % | * | * | 0 | 0 | 0 | 0 |
| Other/Unk | 35 | 0.2 % | 13 | 0.2 % | * | * | 0 | 0 | 0 | 0 |
| Age Category [†] | | | | | | | | | | |
| Unknown | 93 | 0.6 % | 41 | 0.7 % | * | * | 0 | 0 | 0 | 0 |
| 0-12 | 17 | 0.1 % | 20 | 0.3 % | 0 | 0 | 0 | 0 | 0 | 0 |
| 13-19 | 69 | 0.5 % | 30 | 0.5 % | * | * | 0 | 0 | 0 | 0 |
| 20-24 | 383 | 2.8 % | 110 | 2.0 % | 16 | 8.0 % | 0 | 0 | 0 | 0 |
| 25-29 | 1,059 | 7.7 % | 257 | 4.7 % | 36 | 18.1 % | * | * | 0 | 0 |
| 30-39 | 2,192 | 16.0 % | 851 | 15.6 % | 63 | 31.8 % | * | * | * | * |
| 40-49 | 2,990 | 21.9 % | 1,608 | 29.4 % | 30 | 15.1 % | * | * | * | * |
| 50+ | 6,812 | 50.0 % | 2,535 | 46.4 % | 46 | 23.2 % | * | * | * | * |
| Transmission Risk | | | | | | | | | | |
| Sexual Contact | 9,598 | 70.4 % | 3,685 | 67.5 % | 152 | 76.7 % | 7 | 87.5 % | * | * |
| PWID | 3,596 | 26.4 % | 1,467 | 26.9 % | 42 | 21.2 % | 0 | 0 | * | * |
| Pediatric | 146 | 1.0 % | 127 | 2.3 % | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 12 | 0.0 % | * | * | 0 | 0 | 0 | 0 | 0 | 0 |
| No Risk Reported | 263 | 1.9 % | 170 | 3.1 % | * | * | * | * | 0 | 0 |

*Cells size < 6 are suppressed

[†]Age as of December 31, 2015

Note: Gender identity is often not recorded in medical records. Birth sex was used to determine gender identity where no additional information was present. The prevalence among Male to Female, Female to Male, and those cases with additional gender identities is assumed to be higher.


Map 1. Persons Living with HIV/AIDS by Census Tract, Philadelphia, 2015



Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office *The number of cases in this census tract is inflated due to the location of the prison system. Laboratory reports for incarcerated individuals frequently include the address of the prison facility as current address rather than the inmate's home address.

Interactive mapping data is available online at www.AIDSVu.org

Map 2. Newly Diagnosed HIV by Census Tract, Philadelphia, 2015



Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office

*The number of cases in this census tract is inflated due to the location of the prison system. Laboratory reports for incarcerated individuals frequently include the address of the prison facility as address at diagnosis rather than the inmate's home address.


Interactive mapping data is available online at www.AIDSVu.org

| Category | Population | PLWHA | Rate per 100,000 |
|---------------------|------------|--------|------------------|
| Total | 1,526,006 | 19,280 | 1,263.4 |
| Female | 806,193 | 5,478 | 678.2 |
| Male | 719,813 | 13,812 | 1,918.8 |
| Hispanic | 187,611 | 2,911 | 1,551.6 |
| Black | 644,287 | 12,259 | 1,902.7 |
| White | 562,585 | 3,430 | 609.7 |
| Asian | 95,521 | 185 | 193.7 |
| AIAN | 3,498 | 35 | 1,000.6 |
| NHPI | 457 | 13 | 2,844.6 |
| Other Race | 4,105 | * | * |
| Multi-racial | 27,942 | 446 | 1,596.2 |
| Hispanic Female | 94,484 | 793 | 839.3 |
| Black Female | 353,319 | 3,958 | 1,120.2 |
| White Female | 290,025 | 539 | 185.8 |
| Asian Female | 49,137 | 40 | 81.4 |
| AIAN Female | 1,882 | 9 | 478.2 |
| NHPI Female | 237 | * | * |
| Other race Female | 2,014 | 0 | 0.0 |
| Multi-racial Female | 15,095 | 125 | 828.1 |
| Hispanic Male | 93,127 | 2,118 | 2,274.3 |
| Black Male | 290,968 | 8,301 | 2,852.9 |
| White Male | 272,560 | 2,891 | 1,060.7 |
| Asian Male | 46,384 | 145 | 312.6 |
| AIAN Male | 1,616 | 26 | 1,608.9 |
| NHPI Male | 220 | 9 | 4,09.9 |
| Other race Male | 2,091 | * | * |
| Multi-racial Male | 12,847 | 321 | 2,498.6 |

Table 9. Prevalence Rates of HIV/AIDS in Philadelphia, 2015

Note: Rates were calculated using the 2010 decennial census data

Figure 6. HIV/AIDS Prevalence Rates per 100,000 People by Race and Transmission Category, Philadelphia Residents, 2015



*MSM total population based on estimated number of active MSM in the past 5 years
*PWID population estimated as 173 per 10,000 population
*Population of individuals 18 and older living below poverty level
Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office



| | HIV (N | lon-AIDS) | A | IDS | HIV | /AIDS |
|-------------------|--------|-----------|--------|---------|--------|---------|
| | N | % | N | % | N | % |
| Total | 8,568 | 100.0 % | 23,285 | 100.0 % | 31,853 | 100.0 % |
| Race | | | | | | |
| Black | 5,492 | 64.0 % | 15,195 | 65.2 % | 20,687 | 64.9 % |
| White | 1,593 | 18.5 % | 4,879 | 20.9 % | 6,472 | 20.3 % |
| Hispanic | 1,212 | 14.1 % | 2,662 | 11.4 % | 3,874 | 12.1 % |
| Multi-race | 156 | 1.8 % | 415 | 1.7 % | 571 | 1.7 % |
| Asian | 84 | 0.9 % | 113 | 0.4 % | 197 | 0.6 % |
| Other/Unk | 31 | 0.3 % | 21 | 0.0 % | 52 | 0.1 % |
| Sex at Birth | | | | | | |
| Female | 2,507 | 29.2 % | 5,596 | 24.0 % | 8,103 | 25.4 % |
| Male | 6,061 | 70.7 % | 17,689 | 75.9 % | 23,750 | 74.5 % |
| Age Category | | | | | | |
| Unknown | 0 | 0 | 2,574 | 11.0 % | 2,574 | 8.0 % |
| 13-19 | 507 | 5.9 % | 593 | 2.5 % | 1,100 | 3.4 % |
| 20-29 | 2,706 | 31.5 % | 4,910 | 21.0 % | 7,616 | 23.9 % |
| 30-39 | 2,483 | 28.9 % | 7,518 | 32.2 % | 10,001 | 31.3 % |
| 40-49 | 1,825 | 21.3 % | 5,021 | 21.5 % | 6,846 | 21.4 % |
| 50+ | 1,047 | 12.2 % | 2,669 | 11.4 % | 3,716 | 11.6 % |
| Transmission Risk | | | | | | |
| MSM | 3,125 | 36.4 % | 8,160 | 35.0 % | 11,285 | 35.4 % |
| PWID | 1,764 | 20.5 % | 7,697 | 33.0 % | 9,461 | 29.7 % |
| Heterosexual | 3,284 | 38.3 % | 5,894 | 25.3 % | 9,178 | 28.8 % |
| MSM/PWID | 171 | 1.9 % | 1,097 | 4.7 % | 1,268 | 3.9 % |
| Pediatric | * | * | * | * | * | * |
| Other | * | * | 60 | 0.2 % | 65 | 0.2 % |
| No Risk Reported | 217 | 2.5 % | 376 | 1.6 % | 593 | 1.8 % |

Table 11. Cumulative Adult HIV (Non-AIDS) and AIDS Cases by Selected Characteristics, Philadelphia Diagnoses (Diagnosed Through December 31, 2015)

*Cells size < 6 are suppressed

Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office



"I fought for my country. Now I'm bringing the fight to my HIV." 🔲

Reggie - Atlanta, GA Living with HIV since 1985. Hear his story >

Get in care. Stay in care. Live well. 🚱 🛄



Table 12. Concurrent HIV/AIDS, Demographics and Transmission Risk among New HIV Diagnoses, Philadelphia Residents, 2011-2015

| ų | | | | | | | | | | Year | ır | | | | | | | | | |
|---------------------|-------|--------------------|------|------------------------|-----------|--------------------|------|------------------------|-----|--------------------|-----|------------------------|-------|--------------------|-----------------------|------------------------|-------------|--------------------|------------------------|----------------|
| | | 2011 | 11 | | | 2012 | 2 | | | 2013 | 13 | | | 2014 | 4 | | | 2015 | 15 | |
| | CONCI | Non- concurrent | Conc | Concurrent HIV/AIDS | N Conc | Non- concurrent | Conc | Concurrent HIV/AIDS | Nc | Non- concurrent | | Concurrent HIV/AIDS | Conci | Non- concurrent | Concurren HIV/AIDS | Concurrent HIV/AIDS | No concu | Non- concurrent | Concurrent HIV/AIDS | urrent VIDS |
| | z | Col % | z | Col % | z | Col % | z | Col % | z | Col % | z | Col % | z | Col % | z | Col % | z | Col % | z | Col % |
| Total | 503 | 72.5 | 191 | 27.5 | 531 | 72.0 | 206 | 28.0 | 494 | 6'11 | 140 | 22.1 | 444 | 78.0 | 125 | 22.0 | 433 | 80.5 | 105 | 19.5 |
| Sex | | | | | | | | | | | | | | | | | | | | |
| Female | 124 | 76.1 | 39 | 23.9 | 148 | 75.5 | 48 | 24.5 | 91 | 72.8 | 34 | 27.2 | 88 | 74.2 | 31 | 25.8 | 95 | 80.5 | 23 | 19.5 |
| Male | 379 | 71.4 | 152 | 28.6 | 382 | 70.7 | 158 | 29.3 | 403 | 79.2 | 106 | 20.8 | 355 | 79.1 | 94 | 20.9 | 338 | 80.5 | 82 | 19.5 |
| Race/Ethnicity | | | | | | | | | | | | | | | | | | | | |
| Black | 357 | 73.5 | 129 | 26.5 | 369 | 72.6 | 139 | 27.4 | 375 | 79.1 | 66 | 20.9 | 294 | 76.2 | 92 | 23.8 | 312 | 80.0 | 78 | 20.0 |
| Hispanic | 60 | 62.9 | 31 | 34.1 | 81 | 71.1 | 33 | 28.9 | 57 | 82.6 | 12 | 17.4 | ខ | 88.7 | ∞ | 11.3 | 99 | 86.8 | 9 | 13.2 |
| White | 78 | 74.3 | 27 | 25.7 | 69 | 74.2 | 24 | 25.8 | 47 | 69.1 | 21 | 30.9 | 02 | 80.5 | 17 | 19.5 | 46 | 82.1 | 9 | 17.9 |
| Asian | * | 71.4 | * | 28.6 | 9 | 54.6 | * | 45.4 | 7 | 58.3 | * | 41.7 | 9 | 76.9 | * | 23.1 | * | 45.5 | 9 | 54.5 |
| Multi-race | * | 60.0 | * | 40.0 | * | 57.1 | * | 42.9 | * | 66.7 | * | 33.3 | * | 50.0 | * | 50.0 | * | 50.0 | * | 50.0 |
| Other/Unk | 0 | 0 | 0 | 0 | * | 33.3 | * | 66.7 | * | 80.0 | * | 20.0 | * | 75.0 | * | 25.0 | * | 100.0 | 0 | 0 |
| Age at HIV Dx | | | | | | | | | | | | | | | | | | | | |
| 0-12 | * | 100.0 | 0 | 0 | * | 100.0 | 0 | 0 | * | 100.0 | 0 | 0 | * | 100.0 | 0 | 0.0 | * | 100.0 | 0 | 0 |
| 13-19 | 36 | 87.8 | * | 12.2 | 30 | <u>90.9</u> | * | 9.1 | 42 | 95.5 | * | 4.5 | 31 | 93.9 | * | 6.1 | 33 | 97.1 | * | 2.9 |
| 20-24 | 103 | 82.4 | 22 | 17.6 | 124 | 80.5 | 30 | 19.5 | 111 | 84.1 | 21 | 15.9 | 101 | 91.8 | 6 | 8.2 | 96 | 95.0 | * | 5.0 |
| 25-29 | 73 | 75.3 | 24 | 24.7 | 91 | 79.1 | 24 | 20.9 | 82 | 82.0 | 9 | 18.0 | 11 | 88.5 | 9 | 11.5 | 20 | 88.0 | ÷ | 12.0 |
| 30-39 | 109 | 72.2 | 42 | 27.8 | 106 | 72.1 | 41 | 27.9 | 95 | 73.6 | 34 | 26.4 | 88 | 74.2 | 31 | 25.8 | 101 | 78.3 | 28 | 21.7 |
| 40-49 | 113 | 68.9 | 51 | 31.1 | 100 | 64.9 | 54 | 35.1 | 83 | 74.8 | 28 | 25.2 | 62 | 63.9 | 35 | 36.1 | 57 | 64.8 | 31 | 35.2 |
| 50+ | 67 | 58.8 | 47 | 41.2 | 79 | 59.4 | 54 | 40.6 | 76 | 67.3 | 37 | 32.7 | 83 | 68.6 | 38 | 31.4 | 63 | 68.5 | 29 | 31.5 |
| Transmission Risk | | | | | | | | | | | | | | | | | | | | |
| MSM | 221 | 77.3 | 65 | 22.7 | 223 | 74.3 | 11 | 25.7 | 264 | 82.0 | 58 | 18.0 | 247 | 84.9 | 44 | 15.1 | 253 | 83.2 | 51 | 16.8 |
| PWID | 52 | 74.3 | 18 | 25.7 | 63 | 75.9 | 20 | 24.1 | 32 | 80.0 | 80 | 20.0 | 33 | 82.5 | 7 | 17.5 | 27 | 90.0 | * | 10.0 |
| Heterosexual | 212 | 67.7 | 101 | 32.3 | 216 | 69.0 | 97 | 31.0 | 179 | 71.6 | 71 | 28.4 | 153 | 68.0 | 72 | 32.0 | 142 | 75.1 | 47 | 24.9 |
| MSM/PWID | 6 | 69.2 | * | 30.8 | 6 | 90.06 | * | 10.0 | 7 | 87.5 | * | 12.5 | 9 | 100.0 | 0 | 0.0 | * | 50.0 | * | 50.0 |
| Pediatric | * | 100.0 | 0 | 0 | * | 100.0 | 0 | 0 | 9 | 100.0 | 0 | 0 | * | 100.0 | 0 | 0.0 | * | 100.0 | 0 | 0 |
| No Risk Reported | 9 | 66.7 | * | 33.3 | 19 | 63.3 | 4 | 36.7 | 9 | 75.0 | * | 25.0 | * | 66.7 | * | 33.3 | 8 | 72.7 | * | 27.3 |
| | | | | | | | | | | | | | | | | | | | | 1 |

*Cells size < 6 are suppressed

Note: Concurrent HIV/AIDS is defined as diagnosis of AIDS within 90 days of initial diagnosis of HIV Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office

HIV Surveillance Report, Philadelphia

Table 13. Incidence Estimates by Year and Selected Characteristics, Philadelphia Residents,2012- 2014

| | 2012 | | | | 2013 | | | | 2014 | | | |
|------------------------|------|---------|---------|-------------------|------|---------|---------|-------------------|------|---------|---------|-------------------|
| | N | % | 95% CI | Rate [†] | Ν | % | 95% CI | Rate [†] | Ν | % | 95% CI | Rate [†] |
| Total | 618 | 100.00% | 419-817 | 40.5 | 490 | 100.00% | 319-661 | 32.1 | 299 | 100.00% | 205-393 | 19.6 |
| Race | | | | | | | | | | | | |
| Black | 413 | 66.8 % | 257-568 | 64.1 | 380 | 77.6 % | 239-522 | 59.0 | 170 | 56.9 % | 108-231 | 26.4 |
| White | 97 | 15.7 % | 37-157 | 17.2 | 70 | 14.3 % | 0-143 | 12.4 | 51 | 17.1 % | 17-85 | 9.1 |
| Hispanic | 101 | 16.3 % | 34-168 | 53.8 | 33 | 6.7 % | 0-69 | 17.6 | 70 | 23.4 % | 26-114 | 37.3 |
| Other | 8 | 1.3 % | 0-27 | 7.7 | 6 | 1.2 % | 0-35 | 5.8 | 8 | 2.7 % | 0-24 | 7.7 |
| Sex at Birth | | | | | | | | | | | | |
| Male | 449 | 72.7 % | 292-606 | 62.4 | 426 | 86.9 % | 270-582 | 59.2 | 254 | 84.9 % | 168-341 | 35.3 |
| Female | 169 | 27.3 % | 69-269 | 21.0 | 64 | 13.1 % | 13-116 | 7.9 | 44 | 14.7% | 15-74 | 5.5 |
| Age at Infection | | | | | | | | | | | | |
| 13-24 | 213 | 34.5 % | 115-311 | 70.6 | 200 | 40.8 % | 103-296 | 66.3 | 131 | 43.8 % | 76-185 | 43.4 |
| 25-34 | 161 | 26.1 % | 76-246 | 65.4 | 129 | 26.3 % | 53-206 | 52.4 | 85 | 28.4 % | 41-128 | 34.5 |
| 35-44 | 111 | 18.0 % | 39-184 | 58.9 | 76 | 15.5 % | 17-135 | 40.4 | 32 | 10.7 % | 6-58 | 17.0 |
| 45+ | 133 | 21.5 % | 48-218 | 24.4 | 85 | 17.3 % | 22-148 | 15.6 | 51 | 17.1 % | 18-85 | 9.4 |
| Transmission Risk | | | | | | | | | | | | |
| MSM | 284 | 46.0 % | 175-394 | 846.5 | 308 | 62.9 % | 180-437 | 918.1 | 196 | 65.6 % | 122-269 | 584.2 |
| PWID | 70 | 11.3 % | 13-126 | 265.2 | 30 | 6.1 % | 0-69 | 113.6 | 33 | 11.0 % | 6-59 | 125.0 |
| Heterosexual /Other | 264 | 42.7 % | 129-399 | 98.2 | 152 | 31.0 % | 71-232 | 56.5 | 70 | 23.4 % | 33-107 | 26.0 |

Incidence of disease is defined as the number of new infections in a given time period, typically one year. Due to the nature of HIV infection, true incidence is difficult to measure. Recent infection is rarely accompanied with symptoms, and persons are often unaware of their exposure. Routine testing of all persons at risk for HIV is sporadic at best, and many are not tested and diagnosed until some time after their initial infection. The estimates presented here utilize diagnostic testing algorithms designed to detect recent infection, along with testing and treatment history data available for newly diagnosed persons in Philadelphia. These estimates provide the best available indicator of the true number of new HIV infections in Philadelphia. While the rate of incident cases is declining amongst most groups, new HIV transmissions are still affecting certain groups disproportionately. Blacks and Hispanics, males, those aged 13-24, 25-34, and the MSM population are all experiencing the highest percentages of new HIV infections.

[†]*Rate of incident cases are per 100,000 people and based on 2010 decennial census data for race, sex, and age and based on previously used population estimates for MSM, PWID, and high risk heterosexuals. Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office*

Table 14. Perinatal Exposures by Selected Demographics (a) and Clinical Characteristics (b), Philadelphia Residents, 2011–2015

| • | Perinatal Exposures | | | | | |
|-------------------|---------------------|---------|--|--|--|--|
| а. | N | Col % | | | | |
| Total | 315 | 100.0 % | | | | |
| Maternal Age | | | | | | |
| 13-19 | 16 | 5.1 % | | | | |
| 20-24 | 69 | 21.9 % | | | | |
| 25-34 | 161 | 51.1 % | | | | |
| ≥35 | 69 | 21.9 % | | | | |
| Maternal Race | | | | | | |
| Black | 255 | 81.0 % | | | | |
| White | 21 | 6.7 % | | | | |
| Hispanic | 32 | 10.2 % | | | | |
| Other | 7 | 2.2 % | | | | |
| Transmission Risk | | | | | | |
| Heterosexual | 245 | 77.8 % | | | | |
| PWID | 36 | 11.4 % | | | | |
| Pediatric | 17 | 5.4 % | | | | |
| Other/Unk | 17 | 5.4 % | | | | |

Perinatal exposures represent instances where HIV transmission might have occurred from mother to child during pregnancy, labor and delivery (L&D), or breastfeeding. Incidence of HIV infection among perinatally exposed children in Philadelphia has remained low in the past five years due to local perinatal prevention efforts. Data presented in table 14a represent the demographics of the mothers while table 14b represents clinical characteristics of the mother and child before, during, and after birth. Maternal viral load represents the most recent viral load before birth; prenatal care was defined as at least 1 medical visit during pregnancy; maternal timing at diagnosis was categorized as early (any time before L&D), late (during or after L&D), and unknown.

| h | Not | Infected | HIV-Infected | | |
|-------------------------------------|-----|----------|--------------|---------|--|
| b. | N | Col % | Ν | Col % | |
| Total | 310 | 100.0 % | 5 | 100.0 % | |
| Maternal Viral Load | | | | | |
| <1000 | 246 | 79.3 % | 3 | 60.0 % | |
| ≥1000 | 54 | 17.4 % | 1 | 20.0 % | |
| Unknown | 10 | 3.2 % | 1 | 20.0 % | |
| Prenatal care | | | | | |
| Νο | 68 | 21.9 % | 0 | 0 | |
| Yes | 242 | 78.1 % | 5 | 100.0 % | |
| Unknown | | | | | |
| Maternal timing of diagnosis | | | | | |
| Early | 310 | 100.0 % | 5 | 100.0 % | |
| Late | 0 | 0 | 0 | 0 | |
| Unknown | 0 | 0 | 0 | 0 | |
| ARV medications during pregnancy | | | | | |
| Νο | 8 | 2.5 % | 0 | 0 | |
| Yes | 203 | 65.4 % | 4 | 80.0 % | |
| Unknown | 99 | 31.9 % | 1 | 20.0 % | |
| ARV medications during L&D | | | | | |
| No | 38 | 12.2 % | 0 | 0 | |
| Yes | 191 | 61.6 % | 5 | 100.0 % | |
| Unknown | 81 | 26.1 % | 0 | 0 | |
| Neonatal ARV medications | | | | | |
| No | 0 | 0 | 0 | 0 | |
| Yes | 298 | 96.1 % | 5 | 100.0 % | |
| Unknown | 12 | 3.9 % | 0 | 0 | |

*Cells size < 6 are suppressed for demographic data but not clinical data Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office

Table 15. Persons Living with HIV and Hepatitis B or C Co-infection by Selected Characteristics, Philadelphia Residents, 2015[‡]

| | Hepatitis B/HIV | | Hepati | tis C/HIV | HIV/AIDS Total | | |
|-------------------|-----------------|-------|--------|-----------|----------------|---------|--|
| | N | Row % | N | Row % | N | Row % | |
| Total | 984 | 5.1 % | 3,383 | 17.5 % | 19,280 | 100.0 % | |
| Race | | | | | | | |
| Black | 681 | 5.6 % | 1,928 | 15.7 % | 12,259 | 100.0 % | |
| White | 138 | 4.0 % | 611 | 17.8 % | 3,430 | 100.0 % | |
| Hispanic | 119 | 4.1 % | 712 | 24.5 % | 2,911 | 100.0 % | |
| Multi-race | 25 | 5.6 % | 110 | 24.6 % | 446 | 100.0 % | |
| Asian | 17 | 9.1 % | 18 | 9.7 % | 185 | 100.0 % | |
| Other/Unk | * | * | * | * | 49 | 100.0 % | |
| Sex at Birth | | | | | | | |
| Female | 219 | 4.0 % | 987 | 18.0 % | 5,468 | 100.0 % | |
| Male | 765 | 5.5 % | 2,396 | 17.4 % | 13,812 | 100.0 % | |
| Age Category | | | | | | | |
| Unknown | 9 | 6.5 % | 48 | 34.5 % | 139 | 100.0 % | |
| 0-12 | * | * | 0 | 0 | 37 | 100.0 % | |
| 13-19 | * | * | 0 | 0 | 101 | 100.0 % | |
| 20-24 | * | * | 24 | 4.7 % | 509 | 100.0 % | |
| 25-29 | 23 | 1.7 % | 70 | 5.2 % | 1,354 | 100.0 % | |
| 30-39 | 119 | 3.8 % | 370 | 11.9 % | 3,110 | 100.0 % | |
| 40-49 | 295 | 6.4 % | 685 | 14.8 % | 4,632 | 100.0 % | |
| 50+ | 533 | 5.7 % | 2,186 | 23.3 % | 9,398 | 100.0 % | |
| Transmission Risk | | | | | | | |
| MSM | 367 | 5.4 % | 479 | 7.1 % | 6,751 | 100.0 % | |
| PWID | 272 | 6.0 % | 1,086 | 40.1 % | 4,504 | 100.0 % | |
| Heterosexual | 283 | 4.2 % | 837 | 12.5 % | 6,694 | 100.0 % | |
| MSM/PWID | 37 | 6.1 % | 188 | 31.1 % | 605 | 100.0 % | |
| Pediatric | 7 | 2.6 % | 9 | 3.3 % | 273 | 100.0 % | |
| Other | * | * | 8 | 53.3 % | 15 | 100.0 % | |
| No Risk Reported | 18 | 4.1 % | 56 | 12.8 % | 438 | 100.0 % | |

*Cells size < 6 are suppressed

‡Row, not column, percentages are presented here

Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office; Philadelphia Department of Public Health, Division of Disease Control, Viral Hepatitis Program

Definitions

AACO (AIDS Activities Coordinating Office): The office within the Philadelphia Department of Public Health responsible for administering the city's HIV/AIDS Programs.

AIDS (Acquired Immune Deficiency Syndrome): A result of Human Immunodeficiency Virus (HIV) infection, which disables the immune system from effectively fighting numerous opportunistic infections and cancers. **AIAN (American Indiana/ Alaskan Native):** A racial/ethnic group.

CDC (Centers for Disease Control and Prevention): A federal disease prevention agency, which is part of the U.S. Department of Health and Human Services, that provides national laboratory and health and safety guidelines and recommendations; tracks diseases throughout the world; and performs basic research involving laboratory, behavioral science, epidemiology and other studies of disease.

Confidentiality: Keeping medical information confidential or private.

Diagnosis: Determination of the nature of a case of a disease based on signs, symptoms, and laboratory findings during life. A diagnosis of AIDS for an adult is being HIV antibody-positive in addition to having one opportunistic infection, condition, or disease (e.g. wasting syndrome, PCP, Kaposi's sarcoma, CD4 T-lymphocyte count below 200 or 14%).

Epidemiology: The branch of medical science that deals with the study of incidence, distribution and control of a disease in a population.

Gender Identity: One's innermost concept of self as male or female or both or neither—how individuals perceive themselves and what they call themselves. One's gender identity can be the same or different than the sex assigned at birth.

HIV (Human Immunodeficiency Virus): The retrovirus that causes AIDS by infecting the T-helper cells. **Incidence:** The number or rate of new cases of a disease over defined period of time.

MSM (Men who have sex with men): An HIV/AIDS transmission category.

MSM/PWID (Men who have sex with men who are also people who inject drugs): An HIV/AIDS transmission category.

NHPI (Native Hawaiian/ Pacific Islander): A racial/ethnic group.

NIR (No Identified Risk): Indicates when documentation is insufficient to assign an HIV/AIDS transmission category based on CDC guidelines.

Perinatal Transmission of HIV: Term used to describe the spread of HIV/AIDS from a mother to her baby that can occur during pregnancy, labor, delivery or breastfeeding; also known as vertical transmission.

PrEP: Pre-exposure prophylaxis. Antiretroviral medication taken daily by individuals at increased risk for HIV infection to lower their chances of getting infected.

Prevalence: Total number of cases of a disease in a population over a period of time.

PWID (Person/People Who Inject Drugs): An HIV/AIDS transmission category.

Risk Behavior: Used here to describe activities that put people at risk of contracting HIV/AIDS.

Sexual Orientation: The sexual attraction people feel for others, whether of their own sex, the opposite sex, or both sexes.

Transmission Category: A system that classifies cases by possible HIV transmission risk factors or mode(s) of infection; e.g. PWID, MSM/PWID, perinatal transmission, heterosexual contact.

Reporting Information

To Our Readers:

The AACO Surveillance Unit of the Philadelphia Department of Public Health, which conducts HIV/AIDS surveillance for the City of Philadelphia, produces this report. The data in this report reflects cases diagnosed through December 2015 and reported through June 2016.

HIV/AIDS surveillance is the ongoing and systematic collection, analysis, and dissemination of population-based information on HIV/AIDS. There are two basic types of surveillance; active and passive. **Passive surveillance** is the process whereby diagnosing physicians voluntarily submit reports to the Department of Health. **Active surveillance** employs strategies intended to identify unreported cases, and depends on secondary information sources for leads. Information from laboratories, death certificates, direct contact with health care providers, and review of medical records initiate the follow-up investigations. The HIV/AIDS case count in Philadelphia results from a combination of active and passive surveillance. Physicians began reporting AIDS cases to the Department of Health in 1983. Name-based HIV reporting began in October, 2005.

According to the Board of Health's current reporting regulations, health care providers and laboratories are required to report the following: all positive results used as part of the HIV testing algorithm to establish the presence of HIV including preliminary test results if no supplemental/confirmatory test was performed, both detectable and undetectable HIV viral loads, all CD4 results regardless of the level, and all HIV genotypes containing the nucleotide sequence data. Philadelphia facilities and laboratories are also required to submit specimens for HIV incidence testing (STARHS) and are only exempt pending a request submitted to the Philadelphia Health Commissioner.

Cases can be reported on a standard CDC report form to our unit by contacting (215)-685-4789 during the day or by mailing a completed form to:

City of Philadelphia Department of Public Health Post Office Box #58909 Philadelphia, PA 19102-8909

Any Questions about this report and/or requests for data can be directed to:

Tanner Nassau, MPH AACOEPI@PHILA.GOV

Please allow at least 10 business days for all data requests.